N/A N=2,448 First Presentation of Parkinson Disease Patients to Neurologist
Parkinson Disease
Primary: Number of De-novo Patients in Whom Monotherapy With Mirapexin® Could be Successfully Initiated — 403; 323; 73; 15 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=9 Bracing for Walking in Parkinson's Disease
Gait Disorders, Neurologic · Parkinson Disease
Primary: Change in Gait Capacity as Assessed b 6-Minute Walk Test — 235.7; 150.0 Feet
Phase 4 N=40 Namenda (Memantine) for Non-motor Symptoms in Parkinson's Disease
Parkinson's Disease
Primary: Unified Parkinson Disease Rating Scale (UPDRS). — 12; 12; 10; 10 units on a scale
N/A N=9 Effect of Exercise in Parkinsonism
Parkinson's Disease · Drug-induced Parkinsonism
Primary: Change in Dopamine Transporter Imaging — 4.6; -15.9 % change in arbitrary intensity units
Phase 2 N=14 Neurobiological Drivers of Mobility Resilience: The Dopaminergic System
Parkinsonian Signs in Older Persons
Primary: Average Gait Speed — 0.973 meters/second — p=0.015
N/A N=100 Visual Function During Gait in Parkinson's Disease: Impact of Cognition and Response to Visual Cues
Parkinson's Disease
Primary: Visual Sampling Parameter: Saccade Frequency During Gait — 0.48; 0.76; 0.67; 0.77 Saccade frequency (sacc/sec)
N/A N=37 Amyloidopathy, Cholinopathy, Dopamine Responsiveness and Freezing of Gait in PD
Parkinson's Disease
Primary: L-DOPA Insensitivity — 5 Participants — p=0.00468
N/A N=11 The Role of Cerebellar Hyperactivity in Parkinson's Disease
Parkinson's Disease
Primary: Change in Gait Speed- Sham_On — -0.0185 meters per second (m/s)
Phase 2 N=5 Neurobiological Drivers of Mobility Resilience: The Dopaminergic System - Supplemental Open-Label Arm
Parkinsonian Signs in Older Persons
Primary: Average Gait Speed — 0.81; 0.86; 0.86 meters per second
Phase 4 N=9 Lundbeck TOMs Orthostatic Hypotension
Orthostatic Hypotension · Idiopathic Parkinson Disease
Primary: Orthostatic Hypotension Questionnaire (OHQ) Score — 4.6 score on a scale
Phase 2 N=11 Neurobiological Drivers of Mobility Resilience: The Dopaminergic System - Placebo-Controlled Arm
Parkinsonian Signs in Older Persons
Primary: Average Gait Speed — 0.97; 0.86; 1.04; 0.95 meters per second
Phase 4 N=21 The Effect of Donepezil on Gait and Balance in Parkinson's Disease
Parkinson's Disease
Primary: Sensory Organization Test - Composite Score — 7.7; 0.6 score on a scale
Phase 4 N=47 A Study of L-DOPA for Depression and Slowing in Older Adults
Major Depressive Disorder · Dysthymia · Depression Not Otherwise Specified
Primary: Hamilton Rating Scale for Depression (24 Item) — 10.94 Units on a Scale
Phase 2 N=90 Image Parkinson's Disease Progression Study
Parkinson's Disease
Primary: Change in Free-water Accumulation in the Substantia Nigra — 0.0009; 0.0041 arbitrary units (A.U.s)
N/A N=15 Neural Signatures of Parkinson's Disease
Parkinson's Disease
Primary: Change in Resting State Beta Band Power Over Time — -0.28 regression beta coefficient — p=0.038
Phase 4 N=19 Vigor and the LDR in Parkinson Disease
Parkinson Disease
Primary: Tapping Speed Task - Experiment 1 — 110.52; 128.89; 138.43; 145.86 taps/min
N/A N=883 Barriers to Mental Healthcare Utilization in Parkinson's Disease
Parkinson's Disease · Depression · Anxiety
Primary: Most Commonly Reported Past Barrier to Mental Health Services: "Anyone in my Situation Would be Struggling" — 74.8 percentage of total respondents
N/A N=58 Speech, Linguistic and Acoustic Markers in Parkinson's Disease
Parkinson Disease · Cognitive Impairment, Mild · Speech
Primary: Mild Cognitive Impairment — 25; 0; 23; 9 Participants
N/A N=57 Aerobic Exercise in Parkinson's Disease
Parkinson's Disease
Primary: Change in MDS-UPDRS Part III Motor (OFF) Score — 0.44; -2.96 score on scale — p=>0.05
N/A N=19 Genetic Influences on Response to Gait Rehabilitation in Parkinson's Disease
Parkinson's Disease
Primary: Gait Speed (m/s) — 1.14; 1.21; 1.22; 1.20 m/s
N/A N=58 Sing for Your Saunter
Parkinson Disease
Primary: Gait Speed — 1.12; 1.17; 1.04; 1.09 meters per second
N/A N=42 Effect of Levodopa on Postural Motor Learning in Parkinson Disease
Parkinson Disease
Primary: Change in Movement of Center of Mass (COM) After Postural Perturbation — 0.31; 0.28; 0.32; 0.26 meters
N/A N=17 Sing for Your Saunter - Dementia Supplement
Parkinson Disease · Parkinson Disease Dementia
Primary: Velocity — .977; .960; 1.042; 1.011 meters per second
N/A N=32 Prism Adaptation Treatment of Parkinson's Disease
Parkinson
Primary: Change in Postural Control - Reaction Time on the Limits of Stability Test (Smart Equitest Balance Master System) — 0.09; -0.02 Seconds
Phase 4 N=29 Open-Label Study With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease Psychosis
Parkinson Disease Psychosis
Primary: Change From Baseline to Week 16 in Modified Functional Status Questionnaire (mFSQ) Total Score — 14.0 score on a scale — p=<0.0001
N/A N=67 Imaging Biomarkers of Progression of Mobility Impairment in Parkinson Disease
Parkinson's Disease
Primary: AChE PET Neuroimaging — 0.0238; 0.0226 1/min — p=0.0009
N/A N=20 Community Exercise for Fall Risk in PD
Parkinson Disease · Fall · Exercise
Primary: Number of Falls Experienced During the Study Period as Reported by Self-report — 16; 7 self-reported falls
Phase 3 N=40 Effect of Levodopa on Cardiovascular Autonomic Function in Parkinson's Disease
Parkinson Disease · Orthostatic Hypotension
Primary: Change in Systolic Blood Pressure From Supine to Tilt at 3 Minutes — -24.22; -20.32 mmHg
N/A N=45 Nintendo WII and Exercises at Rehabilitation of Individuals With Parkinson's Disease
Parkinson Disease
Primary: Berg Balance Scale — 40.5; 43.9; 41.6; 45.6 Score on a scale
N/A N=87 Usefulness of α-synuclein as a Marker for Early Diagnosis of Parkinson's Disease in Skin Biopsy.
Parkinson Disease · Parkinsonian Disorders
Primary: Demonstrate the Presence of Alpha-Synuclein Inclusions in the Skin of Parkinson's Disease and Compare With an Atypical Parkinsonism Group and With a Healthy Control…